---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-074972"
form_type: "8-K"
ticker: "IRWD"
cik: "0001446847"
company_name: "IRONWOOD PHARMACEUTICALS INC"
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:24:16.741975+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Ironwood Pharmaceuticals Reports Q2 2025 Results; LINZESS U.S. Net Sales $248M, GAAP Net Income $23.6M

## Summary
- LINZESS generated $248M in U.S. net sales in Q2 2025, with 10% year-over-year EUTRx demand growth.
- GAAP net income was $23.6M in Q2 2025, compared to a net loss of $0.9M in Q2 2024.
- Adjusted EBITDA was $50.1M in Q2 2025, up from $36.5M in Q2 2024.
- Company plans to align with FDA on confirmatory Phase 3 trial design for apraglutide in Q4 2025.
- Ironwood is actively progressing a strategic alternatives review to maximize shareholder value.

## SEC filing metadata
- accession: 0001104659-25-074972
- form_type: 8-K
- ticker: IRWD
- cik: 0001446847
- company_name: IRONWOOD PHARMACEUTICALS INC
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1446847/000110465925074972/0001104659-25-074972-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1446847/000110465925074972/tm2522671d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-074972
- JSON: https://secwatch.observer/filing/0001104659-25-074972.json
- Plain text: https://secwatch.observer/filing/0001104659-25-074972.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.